Verve Therapeutics
VERV · NASDAQ
Price unavailable right now.
No price history for this range.
EPS: actual vs estimate
Beat the estimate in 8 of the last 8 quarters, by 20.6% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q1 FY25 | -$0.6687 | -$0.35 | +47.7% |
| Q4 FY24 | -$0.7099 | -$0.58 | +18.3% |
| Q3 FY24 | -$0.7109 | -$0.59 | +17.0% |
| Q2 FY24 | -$0.6977 | -$0.59 | +15.4% |
| Q1 FY24 | -$0.7273 | -$0.59 | +18.9% |
| Q4 FY23 | -$0.8384 | -$0.69 | +17.7% |
| Q3 FY23 | -$0.9364 | -$0.72 | +23.1% |
| Q2 FY23 | -$0.9364 | -$0.87 | +7.1% |
Earnings calls
- Goldman Sachs 46th Annual Global Healthcare Conference 2025
- Jefferies Global Healthcare Conference 2025
- RBC Capital Markets Global Healthcare Conference 2025
- Special Call - Verve Therapeutics, Inc.
- Barclays 27th Annual Global Healthcare Conference 2025
- 43rd Annual J.P. Morgan Healthcare Conference 2025
- Goldman Sachs 45th Annual Global Healthcare Conference
- J.P. Morgan 42nd Annual Healthcare Conference 2024
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.